Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451006 | 1.00 | SIGMAR1 (0.52) | SIGMAR1TAAR1SLC18A2EPHX1CYP2D6 | |
| SCHEMBL12797375 | 1.00 | SIGMAR1 (0.52) | SIGMAR1TAAR1SLC18A2EPHX1CYP2D6 | |
| SCHEMBL30880297 | 0.90 | SLC6A4 (0.47) | SIGMAR1TAAR1SLC18A2SLC6A4 | |
| SCHEMBL1697045 | 0.83 | SIGMAR1 (0.64) | SIGMAR1TAAR1SLC18A2EPHX1CYP2D6 | |
| SCHEMBL13683313 | 0.83 | EPHX1 (0.43) | SIGMAR1TAAR1SLC18A2EPHX1SLC6A2 | |
| SCHEMBL16252283 | 0.81 | SIGMAR1 (0.47) | SIGMAR1TAAR1SLC18A2EPHX1CYP2D6 | |
| SCHEMBL22267909 | 0.81 | TAAR1 (0.48) | SIGMAR1TAAR1SLC18A2EPHX1 | |
| SCHEMBL25590548 | 0.81 | SIGMAR1 (0.55) | SIGMAR1EPHX1SLC6A4 | |
| SCHEMBL13996950 | 0.81 | SIGMAR1 (0.47) | SIGMAR1TAAR1SLC18A2EPHX1CYP2D6 | |
| SCHEMBL19290141 | 0.81 | SIGMAR1 (0.55) | SIGMAR1EPHX1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137607-A1 | THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024035771-A2 | ULK3 INHIBITORS AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-3953334-B1 | NOVEL SYNTHETIC OPTIONS TOWARDS THE MANUFACTURE OF (6R,10S)-10- {4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)- PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15 -(METHENO)PYRAZOLO [4,3-B] [1,7] DIAZACYCLOTETRADECIN-5(6H)-ONE | BRISTOL MYERS SQUIBB CO (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | DAUN JANE | 2011-05-05 | — | — | US | disclosed |
| US-7868002-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20080103137-A1 | Deazapurines and uses thereof | EISAI CO., LTD. | 2008-05-01 | — | — | US | disclosed |
| US-7314936-B2 | Deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | TPMT, CD38, CD2 | SIGMAR1 3124/4885TAAR1 1862/4885SLC18A2 4334/4885 |
| US-20080103137-A1 | Deazapurines and uses thereof | TPMT, TYMP, ENTPD5 | SIGMAR1 4380/4885TAAR1 3834/4885SLC18A2 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.